Ardais Corporation

Ardais, acquired by Gulfstream Bioinformatics Corporation in 2006, was recognized as a leading human tissue repository supporting genomics- and proteomics-based research. It supplied biorepository services to more than 50 major medical institutions and companies.

Ardais collaborated with the University of Pittsburgh Cancer Institute and the Pennsylvania Cancer Alliance Bioinformatics Consortium to demonstrate a National Biospecimen Network (NBN) pilot. The NBN is an initiative of the National Cancer Institute that will provide a national, standardized tissue resource openly accessible to cancer researchers across the country.

 

 

Dyax Corporation

 

 

Dyax was acquired by Shire plc (NASDAQ: SHPC) in 2016.

Dyax developed an approved, wholly-owned drug, KALBITOR, for treating Hereditary Angioedema. UPMC, one of Lancet Capital's Limited Partners, played an important role in the clinical trial for KALBITOR. Andrew McGinnitie of UPMC presented KALBITOR clinical trial data at the American College of Allergy, Asthma, and Immunology's annual meeting.

 

 

Enanta Pharmaceuticals, Inc.

 

 

Enanta is a publicly traded biopharmaceutical company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs in the infectious disease field. It is discovering and developing novel inhibitors designed for use against the hepatitis C virus, or HCV. These inhibitors include members of the direct acting antiviral (DAA) inhibitor classes – protease (partnered with AbbVie, the former research-based pharmaceutical business of Abbott Laboratories), NS5A (partnered with Novartis) and nucleotide polymerase – as well as a host targeted antiviral (HTA) inhibitor class targeted against cyclophilin.

 

 

Scion Pharmaceuticals, Inc.

 

 

Scion was acquired by Wyeth (NYSE: WYE) in 2005, having developed a unique library of ion channel compounds for treating pain. Animal data suggested that its lead pain drug candidate was potentially more efficacious than the leading neuropathic pain therapeutic.

Scion used an integrated strategy of functional genomics, chemistry and High-Throughput ElectroPhysiology (HTEP™) to discover ion channel drugs. HTEP™, licensed exclusively from Boston University, is a unique drug screening technology that permitted the rapid discovery and optimization of small molecule drugs that modulate ion channels.

 

 

Noveome, Inc.

 

 

Noveome, was co-founded and seeded by Lancet Capital. Noveome is the leading innovator in the field of paracrine signaling, a technology platform that has demonstrated safety and efficacy in complex disease processes. Noveome's lead product, ST266, is a rich, complex solution of molecules secreted from proprietary cells. Instead of a single drug and target, the Noveome secretome contains many biologically active molecules, present in physiological concentrations. ST266 has demonstrated therapeutically relevant biologic activity in both preclinical and clinical studies; it has a robust safety profile, and can be manufactured at commercial scale.

 

 

Stentor, Inc.

 

 

Stentor was co-founded and seeded by Lancet Capital. It was acquired by Philips (NYSE: PHG) in 2005.

Stentor developed an enterprise-wide imaging and information solution for the healthcare industry and was the second largest supplier of Picture Archiving and Communication Systems (PACS) in the United States. Its technology was the first viable option for the dynamic real time transfer of high quality images across the healthcare enterprise using existing networks and standard PC's.

Stentor licensed its core technology from the University of Pittsburgh. It conducted beta testing at the University of Pittsburgh Medical Center, which was also a major customer.

 

 

VivoQuest, Inc.

 

 

VivoQuest was co-founded and seeded by Lancet Capital. It was acquired by XTL Biopharmaceuticals (NASDAQ: XTLB) in 2005.

VivoQuest was a drug discovery company with a breakthrough small molecule chemistry technology known as Diversity Oriented Synthesis (“DOS”) for the rapid discovery and development of small molecule drugs derived from natural products.

In collaboration with world class virologists at Rockefeller University, the Company used its proprietary compound libraries and DOS technology to develop a portfolio of small molecule drug leads for the treatment of hepatitis C.